Cabozantinib for Pediatric Cancers

"The age boundaries for participation in this trial are 2 and 18, respectively; all patients below or above these ages will be ineligible."

"Cabozantinib S-malate was initially researched at the Massachusetts General Hospital back in 2011 and since then, 704 studies have been successfully completed. At present, 98 trials are still being conducted with a significant portion of them located within San Francisco."

"Eligible subjects for this medical experiment must have a primary central nervous system neoplasm and be between the ages of 2-18. A total of 41 individuals are needed to fill out the trial."

"Initially researched in 2011, cabozantinib S-malate has been granted Phase 2 drug approval following its first trial conducted by Exelixis. As of now, 98 trials are underway at 1382 sites within 46 countries worldwide."

"Subsequently to our assessment, the safety of cabozantinib S-malate was rated a 1 due to this being an early Phase 1 trial and only limited data supporting efficacy or safety."

"This clinical trial is enrolling participants at UCSF Medical Center-Mission Bay in San Francisco, California; National Institutes of Health Clinical Center in Bethesda, Maryland; and Children's National Medical Center in Washington, District of Columbia. Additionally, the study has 25 other sites located throughout the United States."

"Cabozantinib S-malate is typically given to people who have already been treated with anti-VEGF medications. Apart from that, it also has applications for advanced renal cell carcinoma (ARCC), adrenal medulla and high risk patients suffering from various conditions."

"At the current time, this particular medical study is not actively recruiting. It was first advertised on November 14th 2012 and last edited on September 26th 2023. However, there are 5899 other clinical trials looking for patients with primary central nervous system neoplasm and 98 studies involving cabozantinib S-malate that are welcoming participants."

"Unfortunately, this trial has closed its recruitment period; initial posting was on November 14th 2012 and the last edit occurred September 26th 2023. For those seeking an alternative study, there are presently 5899 trials recruiting patients with primary central nervous system neoplasms and 98 different studies enrolling participants for cabozantinib S-malate treatment."